Stockreport

AVROBIO Announces 87% Substrate Reduction in First Kidney Biopsy and Additional Positive Data from Clinical Trials of AVR-RD-01 Investigational Gene Therapy in Fabry Disease

AVROBIO, Inc.  (AVRO) 
Last avrobio, inc. earnings: 11/7 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: investors.avrobio.com/investor-relations
PDF – 87% reduction in average number of Gb3 inclusions in first kidney biopsy taken one year post-treatment, the primary efficacy endpoint in the Phase 2 trial– Plasma lyso [Read more]